The Rac1 Inhibitor NSC23766 Exerts Anti-Influenza Virus Properties by Affecting the Viral Polymerase

The frequent emergence of new influenza viruses in the human population underlines the urgent need for antiviral therapeutics in addition to the preventative vaccination against the seasonal flu. To circumvent the development of resistance, recent antiviral approaches target cellular proteins needed...

Authors: Dierkes, Rüdiger
Warnking, Kathrin
Liedmann, Swantje
Seyer, Roman
Ludwig, Stephan
Ehrhardt, Christina
Division/Institute:FB 13: Biologie
Document types:Article
Media types:Text
Publication date:2014
Date of publication on miami:17.03.2014
Modification date:16.04.2019
Edition statement:[Electronic ed.]
Source:PLoS ONE 9 (2014) 2, e88520
DDC Subject:610: Medizin und Gesundheit
License:CC BY 4.0
Language:English
Notes:Finanziert durch den Open-Access-Publikationsfonds 2013/2014 der Deutschen Forschungsgemeinschaft (DFG) und der Westfälischen Wilhelms-Universität Münster (WWU Münster).
Format:PDF document
URN:urn:nbn:de:hbz:6-83389592076
Other Identifiers:DOI: 10.1371/journal.pone.0088520
Permalink:https://nbn-resolving.de/urn:nbn:de:hbz:6-83389592076
Digital documents:journal.pone.0088520.pdf

The frequent emergence of new influenza viruses in the human population underlines the urgent need for antiviral therapeutics in addition to the preventative vaccination against the seasonal flu. To circumvent the development of resistance, recent antiviral approaches target cellular proteins needed by the virus for efficient replication. We investigated the contribution of the small GTPase Rac1 to the replication of influenza viruses. Inhibition of Rac1 by NSC23766 resulted in impaired replication of a wide variety of influenza viruses, including a human virus strain of the pandemic from 2009 as well as highly pathogenic avian virus strains. Furthermore, we identified a crucial role of Rac1 for the activity of the viral polymerase complex. The antiviral potential of NSC23766 was confirmed in mouse experiments, identifying Rac1 as a new cellular target for therapeutic treatment of influenza virus infections.